- Home
- INDP vs QNRX Comparison
INDP vs QNRX Comparison
Compare INDP & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INDP
- QNRX
- Stock Information
- Founded
- INDP 2000
- QNRX 2018
- Country
- INDP United States
- QNRX United States
- Employees
- INDP N/A
- QNRX N/A
- Industry
- INDP Biotechnology: Pharmaceutical Preparations
- QNRX Medical/Dental Instruments
- Sector
- INDP Health Care
- QNRX Health Care
- Exchange
- INDP Nasdaq
- QNRX Nasdaq
- Market Cap
- INDP 6.0M
- QNRX 4.8M
- IPO Year
- INDP N/A
- QNRX N/A
- Fundamental
- Price
- INDP $3.62
- QNRX $7.59
- Analyst Decision
- INDP Strong Buy
- QNRX
- Analyst Count
- INDP 2
- QNRX 0
- Target Price
- INDP $238.00
- QNRX N/A
- AVG Volume (30 Days)
- INDP 1.4M
- QNRX 130.9K
- Earning Date
- INDP 11-11-2025
- QNRX 11-06-2025
- Dividend Yield
- INDP N/A
- QNRX N/A
- EPS Growth
- INDP N/A
- QNRX N/A
- EPS
- INDP N/A
- QNRX N/A
- Revenue
- INDP N/A
- QNRX N/A
- Revenue This Year
- INDP N/A
- QNRX N/A
- Revenue Next Year
- INDP N/A
- QNRX N/A
- P/E Ratio
- INDP N/A
- QNRX N/A
- Revenue Growth
- INDP N/A
- QNRX N/A
- 52 Week Low
- INDP $2.22
- QNRX $5.01
- 52 Week High
- INDP $58.24
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- INDP 45.47
- QNRX 52.72
- Support Level
- INDP $2.86
- QNRX $6.93
- Resistance Level
- INDP $4.50
- QNRX $7.41
- Average True Range (ATR)
- INDP 0.99
- QNRX 0.49
- MACD
- INDP 0.25
- QNRX 0.01
- Stochastic Oscillator
- INDP 19.01
- QNRX 48.42
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.